NFKB1 and cancer: The results showed 87 signal pathways (p-value < 0.05) in which geniposide interfered with CRC, mainly involving pathways in the cancer signaling pathway, PI3K–Akt signaling pathway, IL-17 signaling pathway, p53 signaling pathway, NF-κB signaling pathway, and NOD-like receptor signaling pathway, as shown in Figure 8.